{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T17:52:49Z","timestamp":1791309169500,"version":"4.3.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100011096","name":"Jazz Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011096","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"DOI":"10.1007\/s40120-026-01046-3","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T17:21:13Z","timestamp":1791307273000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Narcolepsy and Idiopathic Hypersomnia Real-World Treatment Patterns and Changes in Alerting Agent Use After Low-Sodium Oxybate Initiation: A Retrospective Claims Analysis"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2873-0358","authenticated-orcid":false,"given":"Sarah C.","family":"Markt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisa","family":"Whalen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica K.","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0006-734X","authenticated-orcid":false,"given":"Caroleen","family":"Drachenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2273-231X","authenticated-orcid":false,"given":"Natalie","family":"Gavrielov-Yusim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1071-802X","authenticated-orcid":false,"given":"Silky","family":"Beaty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth M.","family":"Poole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Kroner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dionna","family":"Attinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaina","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jed","family":"Black","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Thorpy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,6]]},"reference":[{"key":"1046_CR1","volume-title":"International classification of sleep disorders\u2014third edition, text revision","author":"American Academy of Sleep Medicine","year":"2023","unstructured":"American Academy of Sleep Medicine. International classification of sleep disorders\u2014third edition, text revision. Darien: American Academy of Sleep Medicine; 2023."},{"issue":"3","key":"1046_CR2","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.jsmc.2017.03.009","volume":"12","author":"LM Trotti","year":"2017","unstructured":"Trotti LM. Idiopathic hypersomnia. Sleep Med Clin. 2017;12(3):331\u201344.","journal-title":"Sleep Med Clin"},{"issue":"2","key":"1046_CR3","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1080\/17460441.2022.1999226","volume":"17","author":"G Junnarkar","year":"2022","unstructured":"Junnarkar G, Allphin C, Profant J, et al. Development of a lower-sodium oxybate formulation for the treatment of patients with narcolepsy and idiopathic hypersomnia. Expert Opin Drug Discov. 2022;17(2):109\u201319.","journal-title":"Expert Opin Drug Discov"},{"key":"1046_CR4","unstructured":"Lumryz\u2122 (sodium oxybate) for extended-release oral solution, CIII [prescribing information]. Chesterfield, MO: Avadel CNS Pharmaceuticals; 2024."},{"key":"1046_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.smrv.2023.101766","volume":"69","author":"I Arnulf","year":"2023","unstructured":"Arnulf I, Thomas R, Roy A, Dauvilliers Y. Update on the treatment of idiopathic hypersomnia: progress, challenges, and expert opinion. Sleep Med Rev. 2023;69:101766.","journal-title":"Sleep Med Rev"},{"issue":"19","key":"1046_CR6","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1056\/NEJM199511093331917","volume":"333","author":"A Szarfman","year":"1995","unstructured":"Szarfman A, Kuchenberg T, Soreth J, Lajmanovich S. Declaring the sodium content of drug products. N Engl J Med. 1995;333(19):1291.","journal-title":"N Engl J Med"},{"key":"1046_CR7","unstructured":"US Food and Drug Administration. Clinical review for Binosto, NDA 202344: US Food and Drug Administration; 2012. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/202344Orig1s000MedR.pdf. Accessed 21 Sept 2026."},{"key":"1046_CR8","unstructured":"US Food and Drug Administration. Quantitative labeling of sodium, potassium, and phosphorus for human over-the-counter and prescription drug products. Guidance for industry Silver Spring, MD: US Food and Drug Administration; 2022. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/quantitative-labeling-sodium-potassium-and-phosphorus-human-over-counter-and-prescription-drug. Accessed 21 Sept 2026."},{"issue":"6","key":"1046_CR9","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1111\/cts.13087","volume":"14","author":"C Chen","year":"2021","unstructured":"Chen C, Jenkins J, Zomorodi K, Skowronski R. Pharmacokinetics, bioavailability, and bioequivalence of lower-sodium oxybate in healthy participants in 2 open-label, randomized, crossover studies. Clin Transl Sci. 2021;14(6):2278\u201387.","journal-title":"Clin Transl Sci"},{"issue":"1","key":"1046_CR10","doi-asserted-by":"publisher","first-page":"19","DOI":"10.5935\/1984-0063.20170004","volume":"10","author":"J Bhattarai","year":"2017","unstructured":"Bhattarai J, Sumerall S. Current and future treatment options for narcolepsy: a review. Sleep Sci. 2017;10(1):19\u201327.","journal-title":"Sleep Sci"},{"issue":"1","key":"1046_CR11","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jsmc.2016.10.013","volume":"12","author":"P Saini","year":"2017","unstructured":"Saini P, Rye DB. Hypersomnia: evaluation, treatment, and social and economic aspects. Sleep Med Clin. 2017;12(1):47\u201360.","journal-title":"Sleep Med Clin"},{"key":"1046_CR12","unstructured":"Market clarity: linked EHR and claims data. Optum. 2025. https:\/\/business.optum.com\/en\/data-analytics\/life-sciences\/real-world-data\/market-clarity-data.html. Accessed 21 Sept 2026."},{"issue":"9","key":"1046_CR13","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.5664\/jcsm.9328","volume":"17","author":"K Maski","year":"2021","unstructured":"Maski K, Trotti LM, Kotagal S, et al. Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2021;17(9):1881\u201393.","journal-title":"J Clin Sleep Med"},{"key":"1046_CR14","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.5664\/jcsm.11834","volume":"21","author":"RM Lloyd","year":"2025","unstructured":"Lloyd RM, Crawford T, Donald R, et al. Quality measure for care of patients with narcolepsy: 2025 update after measure maintenance. J Clin Sleep Med. 2025;21:1943\u201351.","journal-title":"J Clin Sleep Med"},{"issue":"6","key":"1046_CR15","doi-asserted-by":"publisher","first-page":"841","DOI":"10.5664\/jcsm.11072","volume":"20","author":"WJ Healy","year":"2024","unstructured":"Healy WJ, Johnson DA, Liu X, Jean-Louis G, Kwon Y. Disparities in sleep care and cardiovascular outcomes: defining the problem and implementing solutions. J Clin Sleep Med. 2024;20(6):841\u20134.","journal-title":"J Clin Sleep Med"},{"issue":"2","key":"1046_CR16","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.sleh.2023.02.002","volume":"9","author":"E Holler","year":"2023","unstructured":"Holler E, Campbell NL, Boustani M, Dexter P, Ben Miled Z, Owora A. Racial disparities in the pharmacological treatment of insomnia: a time-to-event analysis using real-world data. Sleep Health. 2023;9(2):128\u201335.","journal-title":"Sleep Health"},{"key":"1046_CR17","doi-asserted-by":"publisher","first-page":"89","DOI":"10.2147\/NSS.S386021","volume":"15","author":"LD Schneider","year":"2023","unstructured":"Schneider LD, Stevens J, Husain AM, et al. Symptom severity and treatment satisfaction in patients with idiopathic hypersomnia: the Real World Idiopathic Hypersomnia Outcomes Study (ARISE). Nat Sci Sleep. 2023;15:89\u2013101.","journal-title":"Nat Sci Sleep"},{"key":"1046_CR18","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.sleep.2020.08.034","volume":"75","author":"LM Trotti","year":"2020","unstructured":"Trotti LM, Ong JC, Plante DT, Friederich Murray C, King R, Bliwise DL. Disease symptomatology and response to treatment in people with idiopathic hypersomnia: initial data from the Hypersomnia Foundation Registry. Sleep Med. 2020;75:343\u20139.","journal-title":"Sleep Med"},{"key":"1046_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.sleep.2025.106627","volume":"133","author":"A Chattaraj","year":"2025","unstructured":"Chattaraj A, Freeman AA, Nichols KJ, et al. Idiopathic hypersomnia symptoms over time: longitudinal follow up from the Hypersomnia Foundation registry. Sleep Med. 2025;133:106627.","journal-title":"Sleep Med"},{"issue":"2","key":"1046_CR20","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1111\/ane.13532","volume":"145","author":"H Gauffin","year":"2022","unstructured":"Gauffin H, Fast T, Komkova A, Berntsson S, Bostr\u00f6m I, Landtblom AM. Narcolepsy treatment in Sweden: an observational study. Acta Neurol Scand. 2022;145(2):185\u201392.","journal-title":"Acta Neurol Scand"},{"issue":"1","key":"1046_CR21","doi-asserted-by":"publisher","DOI":"10.1093\/sleepadvances\/zpae085","volume":"5","author":"A Giertz","year":"2024","unstructured":"Giertz A, Mesterton J, Jakobsson T, Crawford S, Ghosh S, Landtblom AM. Epidemiology, patient characteristics, and treatment patterns of patients with narcolepsy in Sweden: a non-interventional study using secondary data. Sleep Adv. 2024;5(1):zpae085.","journal-title":"Sleep Adv"},{"issue":"4","key":"1046_CR22","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s41105-022-00406-4","volume":"20","author":"A Imanishi","year":"2022","unstructured":"Imanishi A, Kamada Y, Shibata K, Sakata Y, Munakata H, Ishii M. Prevalence, incidence, and medications of narcolepsy in Japan: a descriptive observational study using a health insurance claims database. Sleep Biol Rhythms. 2022;20(4):585\u201394.","journal-title":"Sleep Biol Rhythms"},{"issue":"10","key":"1046_CR23","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1111\/pcn.13290","volume":"75","author":"A Imanishi","year":"2021","unstructured":"Imanishi A, Omori Y, Ishido H, et al. Aripiprazole as a new treatment for the prolonged nocturnal sleep of patient with idiopathic hypersomnia. Psychiatry Clin Neurosci. 2021;75(10):320\u20132.","journal-title":"Psychiatry Clin Neurosci"},{"key":"1046_CR24","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.sleep.2016.04.004","volume":"33","author":"J Black","year":"2017","unstructured":"Black J, Reaven NL, Funk SE, et al. Medical comorbidity in narcolepsy: findings from the Burden of Narcolepsy Disease (BOND) study. Sleep Med. 2017;33:13\u20138.","journal-title":"Sleep Med"},{"issue":"10","key":"1046_CR25","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsad161","volume":"46","author":"RH Ben-Joseph","year":"2023","unstructured":"Ben-Joseph RH, Saad R, Black J, et al. Cardiovascular burden of narcolepsy disease (CV-BOND): a real-world evidence study. Sleep. 2023;46(10):zsad161.","journal-title":"Sleep"},{"key":"1046_CR26","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.2147\/NSS.S498213","volume":"17","author":"R Saad","year":"2025","unstructured":"Saad R, Markt SC, Lillaney P, et al. The clinical and economic burden of idiopathic hypersomnia and narcolepsy: a United States claims-based analysis. Nat Sci Sleep. 2025;17:1809\u201323.","journal-title":"Nat Sci Sleep"},{"key":"1046_CR27","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.2147\/NSS.S498432","volume":"17","author":"R Saad","year":"2025","unstructured":"Saad R, Markt SC, Lillaney P, et al. The clinical and economic burden of idiopathic hypersomnia: results from the Real-World Idiopathic Hypersomnia Total Health Model (RHYTHM) study. Nat Sci Sleep. 2025;17:1743\u201355.","journal-title":"Nat Sci Sleep"},{"issue":"1","key":"1046_CR28","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/s12877-017-0621-2","volume":"17","author":"N Masnoon","year":"2017","unstructured":"Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017;17(1):230.","journal-title":"BMC Geriatr"},{"key":"1046_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph18189606","author":"J Gonz\u00e1lez-Bueno","year":"2021","unstructured":"Gonz\u00e1lez-Bueno J, Sevilla-S\u00e1nchez D, Puigoriol-Juvanteny E, Molist-Brunet N, Codina-Jan\u00e9 C, Espaulella-Panicot J. Factors associated with medication non-adherence among patients with multimorbidity and polypharmacy admitted to an intermediate care center. Int J Environ Res Public Health. 2021.\u00a0https:\/\/doi.org\/10.3390\/ijerph18189606.","journal-title":"Int J Environ Res Public Health"},{"key":"1046_CR30","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.sleep.2017.03.028","volume":"35","author":"P Drakatos","year":"2017","unstructured":"Drakatos P, Lykouras D, D\u2019Ancona G, Higgins S, Gildeh N, Macavei R, et al. Safety and efficacy of long-term use of sodium oxybate for narcolepsy with cataplexy in routine clinical practice. Sleep Med. 2017;35:80\u20134.","journal-title":"Sleep Med"},{"key":"1046_CR31","unstructured":"Xyrem\u00ae (sodium oxybate) oral solution, CIII [prescribing information]. Palo Alto, CA: Jazz Pharmaceuticals, Inc.; 2025 July 2025."},{"key":"1046_CR32","unstructured":"Provigil [package insert]. North Wales, PA: Teva Pharmaceuticals; 2018 November 2018."},{"key":"1046_CR33","unstructured":"Ritalin [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2019 November 2019."},{"key":"1046_CR34","unstructured":"Sunosi\u00ae (solriamfetol) tablets Prescribing Information. New York, NY, USA: Axsome Therapeutics, Inc.; 2023 June 2023."},{"key":"1046_CR35","unstructured":"Adderall [package insert]. Horsham, PA: Teva Pharmaceuticals; 2017 January 2017."},{"key":"1046_CR36","unstructured":"Wakix [package insert]. Plymouth Meeting, PA: Harmony Biosciences; 2025 May\u00a02025."},{"key":"1046_CR37","unstructured":"Cigna Healthcare. Neurology\u2014oxybate products prior authorization policy. 2024 [updated November 13, 2024]. https:\/\/static.cigna.com\/assets\/chcp\/pdf\/coveragePolicies\/cnf\/cnf_643_coveragepositioncriteria_neurology_oxybate_products_pa.pdf. Accessed 21 Sept 2026."},{"key":"1046_CR38","unstructured":"CVS Caremark. Specialty guideline management Xywav. 2025. https:\/\/info.caremark.com\/content\/dam\/enterprise\/caremark\/microsites\/dig\/pdfs\/pa_forms_default\/4045-A_Xywav.pdf. Accessed 21 Sept 2026."},{"key":"1046_CR39","unstructured":"UnitedHealthcare. 2026 P 2021-20 program prior authorization\/medical necessity. 2026. https:\/\/www.uhcprovider.com\/content\/dam\/provider\/docs\/public\/prior-auth\/drugs-pharmacy\/commercial\/h-p\/PA-Med-Nec-Narcolepsy-Lumryz-Xyrem-Xywav.pdf. Accessed 28 Sept 2026."},{"issue":"5","key":"1046_CR40","first-page":"233","volume":"10","author":"MJ Thorpy","year":"2017","unstructured":"Thorpy MJ, Hiller G. The medical and economic burden of narcolepsy: implications for managed care. Am Health Drug Benef. 2017;10(5):233\u201341.","journal-title":"Am Health Drug Benef"},{"key":"1046_CR41","unstructured":"Virnig. Strengths and limitations of CMS administrative data in research. Research Data Assistance Center; 2021. https:\/\/resdac.org\/articles\/strengths-and-limitations-cms-administrative-data-research. Accessed 21 Sept 2026."},{"issue":"2","key":"1046_CR42","doi-asserted-by":"publisher","DOI":"10.1093\/sleepadvances\/zpag043","volume":"7","author":"S Ghosh","year":"2026","unstructured":"Ghosh S, Hoffman V, Calingaert B, et al. The prevalence and incidence of narcolepsy in the United States: a real-world observational study using a validated narcolepsy case definition. SLEEP Adv. 2026;7(2):zpag043.","journal-title":"SLEEP Adv"},{"issue":"1","key":"1046_CR43","doi-asserted-by":"publisher","DOI":"10.1093\/sleepadvances\/zpag011","volume":"7","author":"SC Markt","year":"2026","unstructured":"Markt SC, Black J, Bogan RK, et al. Prevalence of diagnosed idiopathic hypersomnia among adults in the United States 2019-2023: analysis of healthcare claims. SLEEP Adv. 2026;7(1):zpag011.","journal-title":"SLEEP Adv"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-01046-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-026-01046-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-01046-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T17:21:16Z","timestamp":1791307276000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-026-01046-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,6]]},"references-count":43,"alternative-id":["1046"],"URL":"https:\/\/doi.org\/10.1007\/s40120-026-01046-3","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,6]]},"assertion":[{"value":"10 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Sarah C. Markt, Marisa Whalen, Jessica K. Alexander, Caroleen Drachenberg, Natalie Gavrielov-Yusim, Silky Beaty, and Elizabeth M. Poole are full-time employees of Jazz Pharmaceuticals, who, in the course of this employment, have received stock options exercisable for, and other stock awards of, ordinary shares of Jazz Pharmaceuticals, plc. John Kroner, Dionna Attinson, and Shaina Desai are full-time employees of Aetion, Inc., and hold stock options or equity in Aetion. Jed Black was a part-time employee of Jazz Pharmaceuticals at the time this research was conducted and is a shareholder of Jazz Pharmaceuticals, plc. Michael J. Thorpy has received research\/grant support and consultancy fees from Axsome, Balance Therapeutics, Eisai Pharmaceuticals, Flamel\/Avadel, Harmony Biosciences, Idorsia Pharmaceuticals, Jazz Pharmaceuticals, NLS Pharmaceuticals, Suven Life Sciences, Takeda Pharmaceuticals, and XWPharma.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All database records are statistically de-identified and certified to be fully compliant with US patient confidentiality requirements set forth in the Health Insurance Portability and Accountability Act of 1996. Because this study used only de-identified patient records and did not involve the collection, use, or transmittal of individually identifiable data, institutional review board approval to conduct this study was not necessary.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}